Pieris Pharmaceuticals Company Profile (NASDAQ:PIRS)

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: PIRS
CUSIP:

Key Metrics:

Previous Close: $1.71
50 Day Moving Average: $1.63
200 Day Moving Average: $1.79
52-Week Range: $1.26 - $3.08
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -2.90
P/E Growth: 0.00
Market Cap: $73.63M
Outstanding Shares: 43,058,000
Beta: 1.66

Profitability:

Net Margins: -346.01%
Return on Equity: -52.21%
Return on Assets: -43.87%

Debt:

Current Ratio: 6.85%
Quick Ratio: 6.85%

Additional Links:

Companies Related to Pieris Pharmaceuticals:

Consensus Ratings for Pieris Pharmaceuticals (NASDAQ:PIRS) (?)

Ratings Breakdown:	3 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$8.33 (387.33% upside)

Analysts' Ratings History for Pieris Pharmaceuticals (NASDAQ:PIRS)

Show:

Date	Firm	Action	Rating	Price Target
8/5/2016	Roth Capital	Reiterated Rating	Buy	$6.00
3/9/2016	JMP Securities	Lower Price Target	Market Outperform	$10.00 -> $9.00
12/8/2015	Oppenheimer Holdings Inc.	Reiterated Rating	Buy	$8.00 -> $10.00

(Data available from 9/28/2014 forward)

Earnings History for Pieris Pharmaceuticals (NASDAQ:PIRS)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/9/2016
8/10/2016	Q216	($0.15)	($0.14)		$1.07 million	View	N/A
5/12/2016	Q116	($0.12)	($0.10)			View	N/A
3/23/2016	Q415	($0.12)	($0.07)	$3.27 million	$2.14 million	View	N/A
11/12/2015	Q315	($0.11)	($0.10)			View	N/A
8/13/2015	Q215	($0.14)	($0.12)		$160.24 million	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Current Year EPS Consensus Estimate: $-0.55 EPS
Next Year EPS Consensus Estimate: $-0.59 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	1	$0.03	$0.03	$0.03
Q2 2016	2	($0.16)	($0.12)	($0.14)
Q3 2016	2	($0.14)	($0.12)	($0.13)
Q4 2016	2	($0.14)	($0.12)	($0.13)

(Data provided by Zacks Investment Research)

Dividend History for Pieris Pharmaceuticals (NASDAQ:PIRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Pieris Pharmaceuticals (NASDAQ:PIRS)

Insider Ownership Percentage: 2.43%
Institutional Ownership Percentage: 45.79%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
6/14/2016	Louis Matis	SVP	Buy	10,000	$1.70	$17,000.00
6/13/2016	Darlene M Deptula-Hicks	CFO	Buy	5,000	$1.66	$8,300.00
6/13/2016	Stephen S Yoder	CEO	Buy	6,000	$1.68	$10,080.00

(Data available from 1/1/2013 forward)

Latest Headlines for Pieris Pharmaceuticals (NASDAQ:PIRS)

Date	Headline
	Penny Stock Investors are Growing Curious About Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Duncan Research (NASDAQ:PIRS) www.duncanindependent.com - September 27 at 6:40 PM
	Shares Spotted Gapping HIgher Pre-Bell: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Post News (NASDAQ:PIRS) www.kentuckypostnews.com - September 27 at 6:40 PM
	Pre-Movers Stocks In Imitation: Williams Companies, Inc. (NYSE:WMB), Pieris Pharmaceuticals, Inc. (PIRS), Turtle ... - Street Wise Report (press release) (blog) (NASDAQ:PIRS) streetwisereport.com - September 27 at 6:40 PM
	Pieris Pharma (PIRS) Says It Presented Positive Data for Lead Drug Candidate PRS-343 - StreetInsider.com (NASDAQ:PIRS) www.streetinsider.com - September 27 at 6:40 PM
	Pieris Pharma Jumps 13% - Unveils Positive Data on Cancer Immunotherapeutic Drug Candidate PRS-343 (NASDAQ:PIRS) www.nasdaq.com - September 27 at 11:22 AM
	Pieris Pharma (PIRS) Says It Presented Positive Data for Lead Drug Candidate PRS-343 (NASDAQ:PIRS) www.streetinsider.com - September 27 at 11:22 AM
	5:16 pm Pieris Pharmaceuticals presents 'positive' data for its bispecific drug candidate, PRS-343 (NASDAQ:PIRS) finance.yahoo.com - September 27 at 11:22 AM
	Pieris Pharmaceuticals Presents Positive Data for Its … (NASDAQ:PIRS) finance.yahoo.com - September 26 at 6:50 PM
	Pieris Pharmaceuticals Presents Positive Data for Its Lead Bispecific Drug Candidate, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (NASDAQ:PIRS) finance.yahoo.com - September 26 at 6:50 PM
	Pieris Pharmaceuticals : Appoints Christopher Kiritsy to Its Board of Directors (NASDAQ:PIRS) www.4-traders.com - September 24 at 11:12 AM
	Under the Microscope, Zeroing in at Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Duncan Research (NASDAQ:PIRS) www.duncanindependent.com - September 23 at 6:17 PM
	Active Runners in Thrust: Tesla Motors (NASDAQ:TSLA), Pieris Pharmaceuticals (NASDAQ:PIRS), Primoris Services ... - Seneca Globe (NASDAQ:PIRS) www.senecaglobe.com - September 23 at 6:17 PM
	Pieris Pharmaceuticals Appoints Christopher Kiritsy to Its Board of Directors (NASDAQ:PIRS) www.marketwired.com - September 22 at 6:27 PM
	Pieris Pharmaceuticals Appoints Christopher Kiritsy to Its Board of Directors - Yahoo Finance (NASDAQ:PIRS) finance.yahoo.com - September 22 at 11:36 AM
	Penny Stock Investors Keen on Shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Duncan Research (NASDAQ:PIRS) www.duncanindependent.com - September 21 at 6:23 PM
	Under the Microscope: Getting a Closer Look at Shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Duncan Research (NASDAQ:PIRS) www.duncanindependent.com - September 19 at 6:42 PM
	Stock Update, a Closer Look at Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Duncan Research (NASDAQ:PIRS) www.duncanindependent.com - September 16 at 10:20 AM
	Keen Investors Narrowing Their Focus on Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Duncan Research (NASDAQ:PIRS) www.duncanindependent.com - September 15 at 10:19 AM
	Penny Stock Investors Highly Curious in Shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Duncan Research (NASDAQ:PIRS) www.duncanindependent.com - September 13 at 11:40 AM
	The Sell-side Consensus is in on Pieris Pharmaceuticals Inc (NASDAQ:PIRS); Earnings & Target Updates - National Daily Press (NASDAQ:PIRS) www.nationaldailypress.com - September 10 at 6:02 PM
	Pieris Pharmaceuticals Announces Presentation of Data for Its Lead IO Bispecific Program, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (NASDAQ:PIRS) finance.yahoo.com - September 7 at 10:19 AM
	Pieris Pharmaceuticals to Present at Rodman & Renshaw 18th Annual Global Investor Conference (NASDAQ:PIRS) finance.yahoo.com - September 1 at 6:44 PM
	How is the Crowd Rating Shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS)? - Post News (NASDAQ:PIRS) www.kentuckypostnews.com - August 24 at 6:36 PM
	Stock Tracking Lower for the Quarter: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Post News (NASDAQ:PIRS) www.kentuckypostnews.com - August 21 at 10:50 AM
	PIERIS PHARMACEUTICALS, INC. Financials (NASDAQ:PIRS) finance.yahoo.com - August 19 at 6:45 PM
	Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:PIRS) www.capitalcube.com - August 12 at 6:58 PM
	PIRS: Development of Multiple Anticalin® Products Continues… (NASDAQ:PIRS) finance.yahoo.com - August 12 at 6:58 PM
	PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:PIRS) biz.yahoo.com - August 11 at 10:05 AM
	Pieris Pharmaceuticals reports 2Q loss (NASDAQ:PIRS) sg.finance.yahoo.com - August 10 at 7:18 PM
	Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) rose 1.39%, The Spectranetics Corporation (NASDAQ:SPNC), General ... - KC Register (NASDAQ:PIRS) www.kcregister.com - August 1 at 11:32 AM
	Pieris Pharmaceuticals to Host Second Quarter 2016 Investor Call and Corporate Update on August 11, 2016 (NASDAQ:PIRS) finance.yahoo.com - August 1 at 8:00 AM
	Pieris Pharmaceuticals Appoints Julian Adams, Ph.D., to Its Board of Directors - Marketwired (press release) (NASDAQ:PIRS) www.marketwired.com - July 27 at 7:13 PM
	PIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and (NASDAQ:PIRS) biz.yahoo.com - July 26 at 9:23 AM
	Checking in on Stock Volatility for: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Engelwood Daily (NASDAQ:PIRS) www.engelwooddaily.com - July 22 at 6:42 PM
	Pieris Pharmaceuticals Inc (NASDAQ:PIRS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:PIRS) www.engelwooddaily.com - July 22 at 6:42 PM
	Pieris Pharmaceuticals Incorporated (NASDAQ:PIRS) Shorted Shares Increased 43.71% After Market Selling - Consumer Eagle (NASDAQ:PIRS) www.consumereagle.com - July 22 at 6:42 PM
	Pieris Pharmaceuticals Inc Stock Technicals at Critical Inflection Point - CML News (NASDAQ:PIRS) news.cmlviz.com - July 21 at 9:43 AM
	Equity Roundup: Stock Performance Focus on Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Press Telegraph (NASDAQ:PIRS) presstelegraph.com - July 21 at 9:43 AM
	Stock Focus: Following Analyst Expectations on Shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - TGP (NASDAQ:PIRS) telanaganapress.com - July 20 at 9:41 AM
	Earnings Focus and Crowd Sourced Sentiment Review for Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - TGP (NASDAQ:PIRS) telanaganapress.com - July 20 at 9:41 AM
	Pieris Pharmaceuticals Incorporated (NASDAQ:PIRS) Sellers Covered 15.84% of Their Shorts - Consumer Eagle (NASDAQ:PIRS) www.consumereagle.com - July 19 at 6:38 AM
	Woodward, Inc. (NASDAQ:WWD) Fell -0.32%: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), Nippon Telegraph and ... - KC Register (NASDAQ:PIRS) www.kcregister.com - July 15 at 5:53 PM
	Trading Performance and Target Watch for Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Press Telegraph (NASDAQ:PIRS) presstelegraph.com - July 15 at 11:58 AM
	Analyst Target and Average Rating Watch: Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Press Telegraph (NASDAQ:PIRS) presstelegraph.com - July 15 at 11:58 AM
	Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:PIRS) www.engelwooddaily.com - July 15 at 11:58 AM
	Pieris Pharmaceuticals Inc Stock Momentum at Critical Inflection Point - CML News (NASDAQ:PIRS) news.cmlviz.com - July 11 at 6:50 PM
	Stock Rating Watch and Earnings Insight for Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Press Telegraph (NASDAQ:PIRS) presstelegraph.com - July 11 at 6:50 PM
	Increased Volatility on Shares of: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Engelwood Daily (NASDAQ:PIRS) www.engelwooddaily.com - July 8 at 6:51 PM
	Can Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Improve on the Earnings Front? - Engelwood Daily (NASDAQ:PIRS) www.engelwooddaily.com - July 8 at 6:51 PM
	Company Stock Focus for Pieris Pharmaceuticals Inc (NASDAQ:PIRS): Which Way Will Shares Head? - Press Telegraph (NASDAQ:PIRS) presstelegraph.com - July 8 at 6:51 PM